Search the Newsreel

Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN

Vistagen Therapeutics (VTGN) announced a non-dilutive financing of up to $100 million with HealthCare Royalty Partners. This agreement extends the company's financial runway into 2027, allowing it to advance its late-stage clinical programs. The initial $50 million will support the Phase 3 PALISADE-2 trial …

Vistagen Therapeutics (VTGN) flags going concern risk amid Q1 loss and Nasdaq pressure

Vistagen Therapeutics reported a net loss of $13.0 million for Q1 2027, an improvement from the prior year, with revenue increasing to $1.5 million. Despite this, the company flagged substantial doubt about its ability to continue as a going concern due to high operating …

William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating

William Blair has reiterated its Hold rating for VistaGen Therapeutics (VTGN.US). The report from the investment firm indicates their continued neutral stance on the company's stock.

Precision Trading with Ncs Multistage Holdings Inc. (NCSM) Risk Zones

This article provides a detailed analysis of Ncs Multistage Holdings Inc. (NCSM) using AI models, highlighting strong sentiment across all horizons. It outlines distinct trading strategies for various risk profiles, including long, breakout, and short setups with specific entry zones, targets, and stop losses. …

Vistagen Therapeutics (VTGN): OrbiMed reports 0.0% beneficial ownership in latest 13G/A

Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake

Chen Yu, through TCG Crossover funds, has reported a 6.7% warrant-based stake in Vistagen Therapeutics (VTGN) via an amended Schedule 13G/A filing. TCG Crossover I holds 1.8% and TCG Crossover II holds 5.1%, with Chen Yu being the sole managing member of both general …

Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026

Vistagen (VTGN) narrows quarterly loss, eyes FDA path after mixed fasedienol data

Vistagen (VTGN) reported a narrower net loss of $13.0 million for Q1 FY2027, an improvement from $15.1 million in the prior-year quarter, largely due to increased revenue and reduced R&D and G&A expenses. While its lead drug fasedienol missed its primary endpoint in the …

VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates

Vistagen Therapeutics Releases Q1 2027 Financial Results

Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …

Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path

(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update. Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. …

Why Stag Industrial (STAG) is a Top Dividend Stock for Your Portfolio

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. Cash flow …

Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026

Vistagen announced its Q1 FY2027 results, reporting $1.476 million in revenue and a net loss of $13.03 million. The company ended the quarter with $31.7 million in cash, expecting these funds to support operations into 2027. Vistagen also highlighted upcoming FDA discussions regarding a …

Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com

This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen announced its fiscal year 2027 first-quarter financial results, highlighting progress in its fasedienol program for social anxiety disorder, including plans for FDA engagement regarding a Phase 3 pathway. The company reported a net loss of $13.0 million, reduced R&D and G&A expenses due …

VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M

* VistaGen Therapeutics press release [https://seekingalpha.com/pr/20619736-vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update] (VTGN [https://seekingalpha.com/symbol/VTGN]): Q1 GAAP EPS of -$0.30 beats by $0.06. * Revenue of $1.48M (+516.7% Y/Y) beats by $1.31M. * Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026. Based on current operating …

Stag Industrial Inc (SW6.DU) stock price, news, quote and history

This Yahoo Finance page provides a financial overview of Stag Industrial Inc (SW6.DU). It includes real-time stock quotes, performance metrics compared to the S&P 500, and links to news, historical data, and financial analysis. The stock is listed on the Dusseldorf exchange and showed …

Bank of America Corp DE Raises Stock Position in Stag Industrial, Inc. $STAG

How Investors Are Reacting To Stagwell (STGW) Q2 Loss, Buybacks, And Governance Shake-Up

How Investors May Respond To STAG Industrial (STAG) EPS Uptick And Affirmed Dividend Amid Softer H1

STAG Industrial reported improved quarterly EPS and affirmed its dividend despite softer net income in the first half of 2026. This mixed financial picture presents a nuanced investment narrative, with the affirmed dividend appealing to income-focused investors while concerns about interest coverage and first-half …

NCS Multistage Holdings Inc (NCSM) Earnings Forecast: Future EPS & Revenue Growth Estimates

Garden Stage Ltd (GSIW) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Garden Stage Ltd (GSIW), focusing on future EPS and revenue growth estimates. It includes a snapshot of the company's current stock performance, market capitalization, and a peer comparison with other investment banking and services firms. The forecast …

Stagwell Inc. $STGW Stock Position Raised by Sei Investments Co.

Stagwell, Inc. Class A Revenue Breakdown – LSX:A3CWMU

Stagwell, Inc. Class A (LSX:A3CWMU) generated 2.48 billion EUR in revenue last year, with its Marketing Services segment contributing 966.21 million EUR. The United States was the primary revenue source, accounting for 1.91 billion EUR. This financial overview provides key insights into the company's …

Stagwell Inc. (STGW) Reports Equity Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stagwell Inc. announced the grant of 77,717 restricted stock units (RSUs) to 10 new employees, effective August 6, 2026. These RSUs, representing Class A common stock, will vest in two installments over two to three years and are subject to accelerated vesting under specific …

(STAG) Movement as an Input in Quant Signal Sets

This article analyzes Stag Industrial Inc. (NASDAQ: STAG) using AI-generated quantitative signals, indicating weak near and mid-term sentiment but a neutral long-term outlook. It highlights an exceptional risk-reward setup targeting a 5.5% gain and outlines three distinct trading strategies: Position Trading, Momentum Breakout, and …

Stag Industrial, Inc. $STAG Shares Purchased by Royal Bank of Canada

Stag Industrial (NYSE:STAG) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded Stag Industrial (NYSE:STAG) from a "hold" to a "sell" rating. Despite this, the broader analyst consensus remains a "hold" with an average price target of $50.50. The company reported Q2 EPS of $0.28, missing estimates, while revenue increased 8.1% year-over-year …

NCS Multistage Holdings Inc (NCSM) Stock News Today

Stag Industrial, Inc. (STAG) Stock Forecasts

Argus has lowered its target price for Stag Industrial, Inc. (STAG) to $36.00, citing its involvement in acquiring and operating single- and multi-tenant industrial properties across the United States. The company is a real estate investment trust, primarily focusing on single-tenant industrial properties. The …

Vistagen (Nasdaq: VTGN) posts Phase 2 fasedienol efficacy signals

Vistagen Therapeutics, Inc. announced topline results from an exploratory Phase 2 study of intranasal fasedienol for social anxiety disorder. The study met its safety objective and showed efficacy signals, particularly in patients with very severe social anxiety, which will inform discussions with the FDA …

Stagwell Extends CEO Mark Penn’s Contract and Compensation

Stagwell Inc. has extended CEO Mark Penn’s employment agreement through July 31, 2029, increasing his annual base salary to $1,400,000 and setting higher bonus and equity incentive targets. The company also granted Penn 2,000,000 cash-settled stock appreciation rights. This move aims to align Penn's …

VistaGen Granted Nasdaq Extension to Regain Bid Compliance

VistaGen Therapeutics has received a 180-day extension from Nasdaq, lasting until February 1, 2027, to meet the $1.00 minimum bid price requirement for its common stock. Failure to comply within this period could lead to delisting. Analysts currently rate VTGN as a Hold with …